Eric Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eric Wu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Tam
Department of Otolaryngology‐Head & Neck Surgery University of Southern California Los Angeles California USA
1 shared publication - Eric M. Yoshida
Division of Gastroenterology, University of British Columbia, British Columbia, Canada
1 shared publication - Kai Zhu
Division of Gastroenterology, University of British Columbia, British Columbia, Canada
1 shared publication - Peter Kwan
Division of Gastroenterology, University of British Columbia, British Columbia, Canada
1 shared publication
Latest Publications
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (4) , 420-423
Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review
We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (4) , 420-423
Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review
We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.